Loading...
OTCM
TBIO
Market cap3mUSD
Jul 09, Last price  
0.05USD
1D
0.00%
1Q
-1.96%
IPO
-99.99%
Name

Codex DNA Inc

Chart & Performance

D1W1MN
OTCM:TBIO chart
P/E
P/S
0.14
EPS
Div Yield, %
Shrs. gr., 5y
-48.32%
Rev. gr., 5y
80.90%
Revenues
28m
+0.27%
001,420,0004,805,0006,576,00011,043,00027,435,00027,509,000
Net income
-48m
L-1.54%
-26,698,000-66,443,000-97,395,000-8,302,000-18,010,000-38,958,000-48,471,000-47,724,000
CFO
-35m
L-10.46%
-23,718,000-50,788,000-22,133,000-6,390,000-15,381,000-36,698,000-38,715,000-34,667,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Telesis Bio, Inc., formerly known as Codex DNA, Inc. (and SGI-DNA, Inc. prior to that), is a San Diego, California-based synthetic biology company established in 2011. The company provides a comprehensive suite of instruments, reagents, and services for synthetic biology applications, catering primarily to pharmaceutical and academic laboratories worldwide. Its clientele also extends to government institutions, contract research organizations (CROs), and other synthetic biology enterprises. Among its core offerings is the BioXp system, a groundbreaking platform that empowers researchers to generate endpoint-ready synthetic DNA directly from digital sequences. Complementing this, the BioXp portal offers an intuitive online environment with guided workflows and design tools for constructing new DNA sequences and assembling them into desired vectors. For specific synthetic biology tasks, Telesis Bio supplies BioXp kits, which include essential building blocks and proprietary reagents like its well-known Gibson Assembly products. Additional solutions encompass cloud-based scripts and specialized benchtop reagents designed for post-BioXp system workflows. Through its Biofoundry Services, customers can commission and receive BioXp system-generated products, such as custom genes, clones, cell-free amplified DNA, and diverse variant libraries. The company also performs enzymatic DNA synthesis using short oligo ligation assembly techniques.
IPO date
Jun 18, 2021
Employees
223
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT